{"id":463,"date":"2020-08-21T09:23:27","date_gmt":"2020-08-21T09:23:27","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=463"},"modified":"2020-08-21T09:23:27","modified_gmt":"2020-08-21T09:23:27","slug":"14-aug-2020-tocilizumab-post-tcz-complications-seen-in-61-patients","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/14-aug-2020-tocilizumab-post-tcz-complications-seen-in-61-patients\/","title":{"rendered":"(14 Aug 2020) Tocilizumab- post TCZ complications seen in 61% patients"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p>Late Onset Infectious Complications and Safety of Tocilizumab in the Management of COVID-19<\/p>\n<p><a href=\"https:\/\/doi.org\/10.1002\/jmv.26429\">https:\/\/doi.org\/10.1002\/jmv.26429<\/a><\/p>\n<p>Seventy-four patients were included in each group. Seven-teen infections in the TCZ group (23%) and 6 (8%) infections in the control group occurred &gt;48 hours after admission (p=0.013). Most infections were bacterial with pneumonia being the most common manifestation. Among patients receiving TCZ, LFT elevations were observed in 51%, neutropenia in 1.4%, and hypertension in 8%. The mortality rate among those that received TCZ was greater than the control (39% versus 23%, p=0.03). CONCLUSION: Late onset infections were significantly more common among those receiving TCZ. Combining infections and TCZ-related toxicities, 61% of patients had a possible post-TCZ complication. While awaiting clinical trial results to establish the efficacy of TCZ for COVID-19 related CRS, the potential for infections and TCZ related toxicities should be carefully weighed when considering use.&nbsp;<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Late Onset Infectious Complications and Safety of Tocilizumab in the Management of COVID-19 https:\/\/doi.org\/10.1002\/jmv.26429 Seventy-four patients were included in each group. Seven-teen infections in the TCZ group (23%) and 6 (8%) infections in the control group occurred &gt;48 hours after&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/14-aug-2020-tocilizumab-post-tcz-complications-seen-in-61-patients\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(14 Aug 2020) Tocilizumab- post TCZ complications seen in 61% patients&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,18],"tags":[27],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/463"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=463"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/463\/revisions"}],"predecessor-version":[{"id":464,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/463\/revisions\/464"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=463"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=463"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=463"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}